Literature DB >> 17270480

Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots.

Helmut Kallwass1, Cortney Carr, Joseph Gerrein, Mariah Titlow, Robert Pomponio, Deeksha Bali, Jian Dai, Priya Kishnani, Alison Skrinar, Deyanira Corzo, Joan Keutzer.   

Abstract

The enzymatic defect in Pompe disease is insufficient lysosomal acid alpha-glucosidase (GAA) activity which leads to lysosomal glycogen accumulation. We recently introduced a simple and reliable method to measure GAA activity in dried blood spots using Acarbose, a highly selective alpha-glucosidase inhibitor, to eliminate isoenzyme interference. Here we demonstrate that this method efficiently detects late-onset Pompe patients who are frequently misdiagnosed by conventional methods due to residual GAA activity in other tissue types.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270480     DOI: 10.1016/j.ymgme.2006.12.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

Authors:  O P van Diggelen; L F Oemardien; N A M E van der Beek; M A Kroos; H K Wind; Y V Voznyi; D Burke; M Jackson; B G Winchester; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2009-04-19       Impact factor: 4.982

2.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

Review 3.  Consensus treatment recommendations for late-onset Pompe disease.

Authors:  Edward J Cupler; Kenneth I Berger; Robert T Leshner; Gil I Wolfe; Jay J Han; Richard J Barohn; John T Kissel
Journal:  Muscle Nerve       Date:  2011-12-15       Impact factor: 3.217

4.  Reference values for lysosomal enzymes activities using dried blood spots samples - a Brazilian experience.

Authors:  Karen B Müller; Mayra Db Rodrigues; Vanessa G Pereira; Ana M Martins; Vânia D'Almeida
Journal:  Diagn Pathol       Date:  2010-09-29       Impact factor: 2.644

5.  Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects.

Authors:  Alfredo Uribe; Roberto Giugliani
Journal:  JIMD Rep       Date:  2013-04-23

6.  Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation.

Authors:  Xiao Liu; Zhaoxia Wang; Weina Jin; He Lv; Wei Zhang; Chengli Que; Yu Huang; Yun Yuan
Journal:  BMC Med Genet       Date:  2014-12-20       Impact factor: 2.103

7.  A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.

Authors:  Yasuyuki Fukuhara; Naoko Fuji; Narutoshi Yamazaki; Asami Hirakiyama; Tetsuharu Kamioka; Joo-Hyun Seo; Ryuichi Mashima; Motomichi Kosuga; Torayuki Okuyama
Journal:  Mol Genet Metab Rep       Date:  2017-10-31

8.  Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology.

Authors:  Khadijeh Haji Naghi Tehrani; Elmira Sakhaeyan; Elnaz Sakhaeyan
Journal:  Electron Physician       Date:  2017-07-25

Review 9.  Establishing Pompe Disease Newborn Screening: The Role of Industry.

Authors:  Joan M Keutzer
Journal:  Int J Neonatal Screen       Date:  2020-07-05

10.  Experience with the Urinary Tetrasaccharide Metabolite for Pompe Disease in the Diagnostic Laboratory.

Authors:  Jennifer T Saville; Maria Fuller
Journal:  Metabolites       Date:  2021-07-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.